"Ten commandments" for conducting comparative effectiveness research using "real-world data".
作者信息
Willke Richard J, Mullins C Daniel
机构信息
Pfizer, Inc, 235 East 42nd Street, New York, NY 10017, USA.
出版信息
J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl A):S10-5. doi: 10.18553/jmcp.2011.17.s9-a.S10.
Abstract
摘要
相似文献
1
"Ten commandments" for conducting comparative effectiveness research using "real-world data".使用“真实世界数据”进行比较效果研究的“十诫”
J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl A):S10-5. doi: 10.18553/jmcp.2011.17.s9-a.S10.
2
It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.需要注意的是，真实世界数据（RWD）永远无法取代更为传统且更为可靠的随机对照试验（RCT）数据；然而，新出现的趋势是纳入更具普遍性的数据。引言。
J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl A):S03-4.
3
Bias in comparative effectiveness studies due to regional variation in medical practice intensity: a legitimate concern, or much ado about nothing?医疗实践强度的地区差异导致的比较效果研究中的偏差：是合理担忧，还是庸人自扰？
Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):e61-4. doi: 10.1161/CIRCOUTCOMES.112.966093.
4
Pre-study feasibility and identifying sensitivity analyses for protocol pre-specification in comparative effectiveness research.比较效果研究中方案预规范的研究前可行性及识别敏感性分析。
J Comp Eff Res. 2014 May;3(3):259-70. doi: 10.2217/cer.14.16.
5
Caveats for the use of operational electronic health record data in comparative effectiveness research.使用操作性电子健康记录数据进行比较有效性研究的注意事项。
Med Care. 2013 Aug;51(8 Suppl 3):S30-7. doi: 10.1097/MLR.0b013e31829b1dbd.
6
Secondary data analysis: techniques for comparing interventions and their limitations.二次数据分析：比较干预措施的技术及其局限性
Curr Opin Urol. 2017 Jul;27(4):354-359. doi: 10.1097/MOU.0000000000000407.
7
Designing quality health services research: why comparative effectiveness studies are needed and why pharmacists should be involved.设计高质量的卫生服务研究：为何需要比较效果研究以及为何药剂师应参与其中。
Pharmacotherapy. 2010 Aug;30(8):751-7. doi: 10.1592/phco.30.8.751.
8
Report outlines best practices in patient-centered outcomes research.报告概述了以患者为中心的结局研究的最佳实践。
Am J Nurs. 2014 Feb;114(2):16. doi: 10.1097/01.NAJ.0000443760.99818.a0.
9
Considerations on the use of patient-reported outcomes in comparative effectiveness research.关于在比较效果研究中使用患者报告结局的思考。
J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl A):S27-33. doi: 10.18553/jmcp.2011.17.s9-a.S27.
10
Effectiveness in the Absence of Efficacy: Cautionary Tales From Real-World Evidence.缺乏疗效时的有效性：来自真实世界证据的警示故事
J Clin Oncol. 2019 May 1;37(13):1047-1050. doi: 10.1200/JCO.18.02105. Epub 2019 Mar 21.
引用本文的文献
1
Transparency in the secondary use of health data: assessing the status quo of guidance and best practices.健康数据二次使用中的透明度：评估指南和最佳实践的现状
R Soc Open Sci. 2025 Mar 26;12(3):241364. doi: 10.1098/rsos.241364. eCollection 2025 Mar.
2
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.美国 Medicare 人群中服用口服抗凝剂的非瓣膜性心房颤动患者住院和医疗费用的真实世界观察性研究。
J Manag Care Spec Pharm. 2020 May;26(5):639-651. doi: 10.18553/jmcp.2020.26.5.639.
3
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.直接口服抗凝剂与华法林治疗美国国防部人群中未经治疗的非瓣膜性心房颤动患者的有效性和安全性比较。
BMC Cardiovasc Disord. 2019 Jun 13;19(1):142. doi: 10.1186/s12872-019-1116-1.
4
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.美国国防部人群中非瓣膜性心房颤动患者口服抗凝剂的真实世界比较有效性、安全性和医疗保健成本。
J Manag Care Spec Pharm. 2018 Nov;24(11):1116-1127. doi: 10.18553/jmcp.2018.17488. Epub 2018 Sep 13.
5
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.美国医疗保险人群中接受口服抗凝剂治疗的非瓣膜性心房颤动患者住院情况及医疗费用的真实世界观察性研究
J Manag Care Spec Pharm. 2018 Sep;24(9):911-920. doi: 10.18553/jmcp.2018.24.9.911.
6
Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making.真实世界数据：为医疗保健决策中使用长期存在的药物补充现有证据的一个机会。
J Multidiscip Healthc. 2018 Jul 2;11:295-304. doi: 10.2147/JMDH.S160029. eCollection 2018.
7
The importance of collecting structured clinical information on multiple sclerosis.收集关于多发性硬化症的结构化临床信息的重要性。
BMC Med. 2016 May 31;14:81. doi: 10.1186/s12916-016-0627-1.
8
Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.医疗保险受益人的低成本通用药物计划使用：对行政索赔数据中药物暴露错误分类的影响。
J Manag Care Spec Pharm. 2016 Jun;22(6):741-51. doi: 10.18553/jmcp.2016.22.6.741.
9
Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.在全国代表性的私人保险成年人队列中，低成本通用药物方案使用的流行率。
J Manag Care Spec Pharm. 2015 Dec;21(12):1162-70. doi: 10.18553/jmcp.2015.21.12.1162.
Zotero 插件